Jiangsu Vanguard Pharmaceutical Co., Ltd. Was established in 2003. The company's main business focuses on the R&D, production, and sales of chemical drugs and traditional Chinese medicines, while also providing drug process development and production services to external clients. It has established R&D centers in Nantong, Nanjing, and Tianjin, equipped with high-end and comprehensive R&D facilities.

Vanguard will continue to maintain high R&D investment, adopting a product development strategy that combines "generic drugs + innovative drugs" to establish a competitive edge and build core competitiveness. Currently, Vanguard independently develops and produces medications for cardiovascular diseases, diabetes and its complications, calcium supplements, antitumor treatments, gastrointestinal disorders, and other fields, creating a diversified product pipeline and a robust R&D and production technology service system.

Vanguard holds 32 invention patents, 37 chemical generic drug registration approvals, and 14 traditional Chinese medicine registration approvals. Among these, 8 products are listed by the National Essential Medicines List, 33 products are included in the National Reimbursement Drug List, and 19 products have passed or are deemed to have passed consistency evaluations.